EPI-NEWS

NATIONAL SURVEILLANCE OF COMMUNICABLE DISEASES

Editor: Peter Henrik Andersen Dept. of Epidemiology

Statens Serum Institut • 5 Artillerivej • DK 2300 Copenhagen S

Tel.: +45 3268 3268 • Fax: +45 3268 3874 www.ssi.dk • epinews@ssi.dk • ISSN: 1396-4798




NEUROBORRELIOSIS 2005-2006

No. 47, 2007

2005-2006 saw a total of 195 neuroborreliosis notifications, including 89 in 2005 and 106 in 2006. In 146 (75%) cases, the diagnosis was confirmed by intrathecal antibody synthesis. A total of 77 (39%) were children below 15 years. The second most frequent age group was adults aged 60-69 years; this group comprised 30 (15%) cases, Figure 1.

Figure 1: Notified cases of neuroborreliosis by age, 2005-2006



Information about symptoms was available in 153 (78%) cases: 72 (37%) had facial nerve palsy, 24 (12%) developed pain in the musculoskeletal system, 23 (12%) headache and three aseptic meningitis. The remaining cases stated that they had experienced other neurological or unspecific symptoms. The majority, 174, were infected in Denmark, while six were infected in Sweden, ten in other European countries and one in the USA. In four cases, several possible countries of infection were stated.

Prophylaxis

To prevent infection with Borrelia, it is important to search the body and remove any ticks. When walking in densely infested areas, it is also advisable to reduce the risk of tick bites by wearing clothes and footwear that cover the body.

Commentary

Borreliosis is the most common vector-borne disease in Denmark. The number of notified cases in 2005-6 equalled the 2003-4 level, see EPI-NEWS 33/05 for details and a short description of epidemiology and symptoms.

A single individual, positive serological test result has limited predictive value and should be interpreted with reference to the clinical picture, etc. The following case description outlines a classical case of neuroborreliosis in an adult patient. The description demonstrates that a negative Borrelia burgdorferi titre in serum from patients with relevant symptomatology does not exclude neuroborreliosis.

(C. Kjelsø, K. Mølbak, Department of Epidemiology)

NEUROBORRELIOSIS CASE STORY

In August 2007, a 54-year-old formerly healthy male was bitten by a tick in the left thigh. Due to erythema migrans, the patient saw a doctor who found no indication for antibiotic treatment. In the first part of September, he experienced radicular pain and visited his GP again. On suspicion of borreliosis, oral penicillin treatment was initiated. Serum Borrelia burgdorferi antibodies were taken with the aim to determine if further assessment was indicated. His condition deteriorated and he was admitted two days after initiation of the penicillin treatment. Upon admission, the patient had endured radicular pain for a period of two to three weeks. The pain started in his left leg, subsequently became more intense, accentuated axially between the shoulder blades and became considerably worse at night. The patient had only limited benefit from paracetamol and non-steroid antiinflammatory drugs.

Paraclinically, WBC count and CRP were determined within the normal range upon admission. On suspicion of neuroborreliosis, the patient underwent lumbal puncture, which showed an increased WBC count (100% mononuclear) and protein in the cerebrospinal fluid. Culture did not result in growth and IV treatment with ceftriaxone 2 g x 1 was initiated to make ambulatory treatment possible. Four days after initiation of IV antibiotics, the patient's pain receded considerably, and medication was changed to doxycycline (200 mg x 2), which was upheld until the total treatment period had reached two weeks. During this final part of the period, the patient's condition improved further.

Serum Borrelia burgdorferi IgG and IgM tested negative. The Borrelia burgdorferi intrathecal antibody synthesis was positive with intrathecal IgG and IgM indexes of 16 and 5, respectively.

Commentary

A negative Borrelia burgdorferi titre in serum from patients who have had neurological symptoms for less than three months does not exclude neuroborreliosis.

On suspicion of neuroborreliosis, tick bite cases with radicular pain and erythema migrans should be admitted for lumbal puncture.
(A-M. Lebech, L.R. Mathiesen, Department of Infectious Diseases, Hvidovre Hospital)

NEW VERSION OF "TRAVELLING AND INFECTIOUS DISEASES"

The SSI website "Rejser og smitsomme sygdomme" (In English: "Travelling and Infectious Diseases") at www.ssi.dk/rejser has been improved.

In future, the maps on the site will be displayed with topographic information. Major cities will be displayed at certain zoom levels. When zooming in on the maps, users will also see regional borders and names within the country in question.

A new addition is the option to display current outbreaks and present the occurrence of a number of infectious diseases within each country. When the user has selected e.g. malaria, a description of risk areas and seasons will be displayed whenever the user places the pointer above a region/country. The website will be updated regularly and the date of the latest update of any outbreak information is displayed in a text box by the outbreak icon on the global map as well as on all country pages. The search facility has been improved and now comprises the names of the cities shown on the map. When searching for the name of a city and clicking the search result, users are sent directly to the page displaying the country, and the map is centred on the city in question. The website is in Danish lanquage.

(P.H. Andersen, Department of Epidemiology)

MANDATORY YELLOW FEVER VACCINATION FOR ALL TRAVELLERS TO BOLIVIA

The Ministry of Foreign Affairs advises that the Bolivian authorities have made yellow fever vaccination mandatory for all travellers entering Bolivia as from 1 December 2007, regardless of the duration of the stay. Vaccination should be given no later than ten days before departure and then remains effective for a period of ten years, see www.ssi.dk/rejser (in Danish language).

(Department of Epidemiology)

Individually notifiable diseases

Number of notifications received in the Department of Epidemiology, SSI (2007 figures are preliminary)

Epideiliology, 551 (2007 figures are preliminary)					
Table 1	Week 46 2007	Cum. 2007 ¹⁾	Cum. 2006 1)		
AIDS	0	44	39		
Anthrax	0	0	0		
Botulism	0	0	0		
Cholera	0	0	0		
Creutzfeldt-Jakob	0	7	18		
Diphtheria	0	0	0		
Food-borne diseases	10	570	515		
of these, infected abroad	1	106	129		
Gonorrhoea	0	314	382		
Haemorrhagic fever	0	0	0		
Hepatitis A	0	21	37		
of these, infected abroad	0	10	19		
Hepatitis B (acute)	0	25	18		
Hepatitis B (chronic)	4	288	282		
Hepatitis C (acute)	0	6	7		
Hepatitis C (chronic)	5	538	424		
HIV	6	280	209		
Legionella pneumonia	4	111	105		
of these, infected abroad	0	31	28		
Leprosy	0	0	0		
Leptospirosis	0	13	8		
Measles	0	2	27		
Meningococcal disease	0	62	73		
of these, group B	0	35	37		
of these, group C	0	19	16		
of these, unspec. + other	0	8	20		
Mumps	3	11	16		
Neuroborreliosis	2	92	76		
Ornithosis	0	8	11		
Pertussis (children < 2 years)	3	74	44		
Plague	0	0	0		
Polio	0	0	0		
Purulent meningitis	0	0	0		
Haemophilus influenzae	0	2	4		
-		10	7		
Listeria monocytogenes	0 0	90	78		
Streptococcus pneumoniae					
Other aethiology	0	12 13	11		
Unknown aethiology	0 3		17		
Under registration		5	-		
Rabies	0	0	0		
Rubella (congenital)	0	0	0		
Rubella (during pregnancy)	0	0	0		
Shigellosis	1	205	58		
of these, infected abroad	1	45	48		
Syphilis	0	87	62		
Tetanus	0	2	2		
Tuberculosis	11	356	336		
Typhoid/paratyphoid fever	1	22	26		
of these, infected abroad	1	21	24		
Typhus exanthematicus	0	2	0		
VTEC/HUS	2	143	127		
of these, infected abroad 1) Cumulative number 2007 and in	correspond	48 ding peri	44 od 2006		

Selected laboratory diagnosed infections


Number of specimens, isolates, and/or notifications received in SSI laboratories

received in SSI laboratories					
Table 2	Week 46 2007	Cum. 2007 ²⁾	Cum. 2006 ²⁾		
Bordetella pertussis					
(all ages)	6	192	193		
Gonococci	4	310	373		
of these, females	3	50	65		
of these, males	1	260	308		
Listeria monocytogenes	1	51	49		
Mycoplasma pneumoniae					
Resp. specimens ³⁾	8	331	416		
Serum specimens 4)	6	379	342		
Streptococci 5)					
Group A streptococci	2	101	124		
Group B streptococci	0	86	85		
Group C streptococci	0	20	20		
Group G streptococci	3	111	130		
S. pneumoniae	18	906	837		
Table 3	Week 44 2007	Cum. 2007 ²⁾	Cum. 2006 ²⁾		
MRSA	19	546	-		
Pathogenic int. bacteria ⁶⁾					
Campylobacter	57	3572	2768		
S. Enteritidis	7	499	518		
S. Typhimurium	6	319	361		
Other zoon. salmonella	5	620	624		
Yersinia enterocolitica	8	239	168		
Verocytotoxin-					
producing E. coli	3	140	131		
Enteropathogenic E. coli	3	167	237		
Enterotoxigenic E. coli	5	268	209		

²⁾ Cumulative number 2007 and in corresponding period 2006

Sentinel surveillance of the influenza activity

Weekly percentage of consultations, 2006/2007/2008



Week no.

Influenza consultations (as percentage of total consultations) Sentinel:

-Sentinel -

Basal curve: Expected frequency of consultations

under non-epidemic conditions

-Basal curve ---- Alert threshold

Possible incipient epidemic Alert threshold:

21 November 2007

 $^{^{3)}}$ Resp. specimens with positive PCR

⁴⁾ Serum specimens with pos. complement fixation test

⁵⁾ Isolated in blood or spinal fluid

⁶⁾ See also www.germ.dk